Back to results
US 7,732,148 B2Granted
Annexin A3 for prostate cancer diagnosis
AssigneeProteosys AG
InventorsMichael Cahill, André Schrattenholz
Life of this patent
Estimating the term…
Abstract
A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.
Claims8
A method of diagnosing prostate cancer and discriminating between cancerous and non-cancerous prostate tissue, comprising the steps of:
- a) providing a prostate massage to a human;
- b) obtaining an exprimate urine sample from the human;
- c) fractionating the exprimate urine sample to produce an insoluble fraction and a supernatant fraction;
- d) determining the abundance of human annexin A3 protein in the insoluble fraction and/or supernatant fraction;
- e) providing a first control value for the abundance of human annexin A3 protein in an insoluble fraction and/or supernatant fraction from a second human known not to have prostate cancer, wherein the insoluble fraction and/or supernatant fraction is obtained from the second human by performing steps a)-d);
- f) comparing the abundance of human annexin A3 protein in the insoluble fraction and/or supernatant fraction to the first control value;
- and
- g) diagnosing the human as having prostate cancer and discriminating between cancerous and non-cancerous tissue, if the abundance of human annexin A3 protein in the insoluble fraction and/or supernatant fraction is less than the first control value;
- wherein the exprimate urine sample, or a fraction thereof, is purified and is free from neutrophils, monocytes or peripheral blood mononuclear cells.
6 more elements
Dependencies are inferred from the claim text.